Non-Small Cell Lung Cancer
sirexatamab (DKN-01) 
Sirexatamab (DKN-01) in lung cancer
DKK1 is highly expressed in NSCLC and associated with shorter overall survival. Sirexatamab (DKN-01) has demonstrated activity as a monotherapy and in combination with chemotherapies and PD-1 antibody immune checkpoint inhibitors in preclinical models of NSCLC. In a clinical trial, sirexatamab (DKN-01) demonstrated single agent activity in heavily-pretreated patients with NSCLC, including a patient with a partial response and nearly 50% of patients experiencing a best response of stable disease.